KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Depreciation and Depletion (2018 - 2025)

Historic Depreciation and Depletion for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $4.0 million.

  • Adaptive Biotechnologies' Depreciation and Depletion fell 446.79% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year decrease of 1114.29%. This contributed to the annual value of $17.6 million for FY2024, which is 1428.01% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Depreciation and Depletion stood at $4.0 million, which was down 446.79% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Depreciation and Depletion peaked at $5.3 million during Q3 2023, and registered a low of $2.3 million during Q1 2021.
  • Its 5-year average for Depreciation and Depletion is $4.3 million, with a median of $4.6 million in 2024.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Depreciation and Depletion skyrocketed by 12843.99% in 2021, and later plummeted by 2196.81% in 2024.
  • Adaptive Biotechnologies' Depreciation and Depletion (Quarter) stood at $4.5 million in 2021, then grew by 8.76% to $4.9 million in 2022, then increased by 2.18% to $5.0 million in 2023, then fell by 18.05% to $4.1 million in 2024, then fell by 2.21% to $4.0 million in 2025.
  • Its Depreciation and Depletion was $4.0 million in Q3 2025, compared to $4.1 million in Q2 2025 and $4.3 million in Q1 2025.